A promising breast-cancer regimen improves response before survival is settled

Neoadjuvant treatment creates an unusually clear window into tumor biology: a therapy can be given before surgery and the removed tissue can reveal whether cancer remains. In the METIS phase II study, 156 patients with stage II–III HER2-positive breast cancer received either a pegylated liposomal doxorubicin-based regimen concurrently with trastuzumab/pertuzumab or a more conventional sequential anthracycline-containing regimen.

Pathological complete response occurred in 67.5% versus 48.7%, an absolute difference of 18.8 percentage points (95% CI 3.6–34.0). This is a meaningful signal. Yet after median follow-up of 37.5 months, the event-free survival hazard ratio was 0.35 with a wide confidence interval (0.09–1.32) and P=0.105; three versus eight events do not establish longer event-free survival. No symptomatic cardiac dysfunction was reported, but a 156-person study cannot settle uncommon late toxicities.

The clinical implication is narrower than the eye-catching response rate. This regimen merits serious phase III evaluation with cardiac monitoring, late safety and long-term disease outcomes. A pathological complete response is a useful intermediate endpoint, but it is not interchangeable with survival, quality of life or freedom from treatment burden.